Uncategorized
Engineered Human Interneuron Transplants Repair Respiratory Circuits in Injured Rats
About 15 to 20 million people globally are impacted by spinal cord injuries, which can impair movement, limit their independence, and disrupt important bodily functions. For example, damage to the spinal cord that occurs at the neck disrupts signals that control the diaphragm, the main muscle used in breathing. The body does not naturally rebuild lost neural connections and there are no approved therapies that can regenerate the neurons and connections affected by a spinal cord injury. But that could change thanks to new research from scientists at Gladstone Institutes.
Full details of the work, which was done in rats, are published in Science Translational Medicine in a new paper “Human spinal interneurons repair the injured rat spinal cord through synaptic integration.” It shows that human stem cell-derived spinal interconnected neurons or interneurons—critical cells for breathing and movement—can survive following transplantation in injured rats, form connections with the receiving animals’ neural circuits, and improve breathing-related motor function. As Lana Zholudeva, PhD, a Gladstone investigator and the paper’s first author, puts it, “this study demonstrates that a specific type of human spinal interneuron can be engineered from stem cells and transplanted into an injured spinal cord” in such a way that “the cells not only survive, but form new pathways to repair damaged networks.”
For the study, the scientists focused on a subtype of the interneurons called V2a interneurons. These are relay cells that play a role in controlling movement. Previous research by Zholudeva’s team and others have shown that these cells are implicated in recovery after traumatic spinal cord injury, including in the neural circuits involved in breathing and walking.
Using human induced pluripotent stem cells, Zholudeva and her team generated transplantable human V2a interneurons that were optimized for repairing injured spinal circuits. Specifically, “we engineered human V2a-enriched SpINs from an optogenetic channelrhodopsin-2 (ChR2) expressing the human induced pluripotent stem cell line,” they wrote in the paper. Getting the process right took some doing, according to Deepak Srivastava, MD, Gladstone president and senior author of the study “it took about a year and a half of trial and error to get the recipe right to make this particular neuron out of stem cells, but it really paid off.” They also ensured that cells could be frozen in vials and later thawed for use, making it possible to use them in human clinical trials down the road.
Next, the scientists transplanted the interneurons into adult rats one week after they sustained injuries to their cervical spinal cords. Two months post transplantation, the scientists found that the new cells not only survived the hostile environment of the injury site but also formed connections with nearby cells. Furthermore, when the scientists activated the transplant site, they observed increased activity in the diaphragm. They also activated the rats’ own brainstem neurons and found that the transplanted cells switched on in response.
The scientists also tested the rats’ breathing under different conditions. Under normal conditions, the difference in the animals’ breathing was less noticeable. But in a low oxygen or high carbon dioxide environment, most of the injured, untreated controls showed signs of respiratory failure. In contrast, most of the rats that received the new V2a interneurons passed the challenges without difficulty. “The transplanted cells seem to be providing that additional capacity,” Zholudeva said.
One component of the study involved looking at why some transplants worked better than others. The scientists identified a specific subset of transplanted V2a interneurons that seemed especially likely to connect with the host animal’s breathing circuit. They plan to follow up on the finding as part of their next steps. Further down the road, they plan to test the potential therapy in larger animals. And they will evaluate whether it is as effective in the injured spinal cord months or years after injury, not just in the immediate aftermath.
The team also hopes to test the treatment in other neural circuits. Specifically, they are considering circuits that control arm and hand function, something that people with cervical spinal cord injuries often identify as their highest priority for recovery. “We’ve shown a proof of principle that this can work, that you can engineer a defined cell type, transplant it, and have it actually repair a specific circuit,” Zholudeva said. “Now we have to make it work more consistently, in more circuits, and eventually in people.”
The post Engineered Human Interneuron Transplants Repair Respiratory Circuits in Injured Rats appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized6 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read